Endolymphatic sac tumor showing increased activity on 68ga dotatate PET/CT
Clinical Nuclear Medicine, 41(10), 783–784
Abstract
Endolymphatic sac tumors (ELSTs) are rare tumors arising from the epithelium of the endolymphatic sac and duct that can be either sporadic or associated with von Hippel-Lindau (VHL) disease. We report a case of a VHL patient with histologically proven residual ELST who underwent Ga DOTATATE PET/CT showing increased activity (SUVmax, 6.29) by the ELST. The presented case of a VHL-associated ELST with increased Ga DOTATATE uptake indicates cell-surface expression of somatostatin receptors by this tumor, suggesting the potential application of somatostatin receptor imaging using Ga DOTA-conjugated peptides in the workup and management of these patients.
Abstract sourceThis 2016 case report describes increased 68Ga DOTATATE uptake in a residual endolymphatic sac tumor in a patient with von Hippel-Lindau disease. The authors discuss the potential relevance of somatostatin receptor imaging, while noting that further investigation is needed.
Summary
The authors report a case of histologically confirmed residual endolymphatic sac tumor in a patient with von Hippel-Lindau disease. The tumor showed increased activity on 68Ga DOTATATE PET/CT, with a reported SUVmax of 6.29. The authors suggest that this observation may indicate somatostatin receptor expression and discuss possible applications of receptor imaging in evaluating these tumors.
This is a single-patient case report. The authors describe potential uses of somatostatin receptor imaging and related approaches, but state that these possibilities require further investigation; the report does not establish diagnostic performance or clinical benefit.
Cite this work
Georgios Z. Papadakis; Corina Millo; Samira M. Sadowski; Ulas Bagci; Nicholas J. Patronas (2016). Endolymphatic sac tumor showing increased activity on 68ga dotatate PET/CT. Clinical Nuclear Medicine, 41(10), 783–784 https://doi.org/10.1097/RLU.0000000000001315
BibTeX